Legal & General Group Plc Purchases Shares of 1,465,529 Zimmer Biomet Holdings, Inc. $ZBH

Legal & General Group Plc acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,465,529 shares of the medical equipment provider’s stock, valued at approximately $126,167,000.

Several other large investors have also modified their holdings of the stock. DV Equities LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth $25,000. Tacita Capital Inc acquired a new position in Zimmer Biomet in the second quarter valued at $26,000. Monetary Solutions Ltd purchased a new position in shares of Zimmer Biomet during the fourth quarter worth about $30,000. Gen Wealth Partners Inc purchased a new position in shares of Zimmer Biomet during the fourth quarter worth about $31,000. Finally, Elevation Wealth Partners LLC increased its position in shares of Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 229 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on ZBH. Canaccord Genuity Group boosted their target price on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. BMO Capital Markets reaffirmed a “market perform” rating and set a $96.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Stifel Nicolaus boosted their price objective on Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Truist Financial increased their price objective on Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a report on Thursday, August 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $99.40 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $106.88. The stock has a market capitalization of $18.96 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 2.76 and a beta of 0.45. The company has a 50-day simple moving average of $93.63 and a 200-day simple moving average of $91.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.